{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Glutamine-Supplemented Parenteral Nutrition in Surgical ICU Patients"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "parallel-group, multicenter, double-blind, randomized controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "conducted in adults post-gastrointestinal, vascular, or cardiac surgery requiring PN and SICU care. Eligible participants were those without significant renal or hepatic failure or shock."
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomized to receive either standard GLN-free PN (STD-PN) or PN containing alanyl-GLN dipeptide (GLN-PN)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the effect of GLN-supplemented PN on clinical outcomes in surgical ICU (SICU) patients."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary endpoints were hospital mortality and infections, measured over the hospital stay."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included patients, clinicians, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 150 participants were randomized, 75 to each group"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "analyzed using an intention-to-treat approach"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Hospital mortality was 14.7% in the GLN-PN group and 17.3% in the STD-PN group (difference, \u22122.6%; 95% CI \u221214.6 to 9.3%; P = 0.66)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar between groups, with no significant differences in frequency or severity."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Trial registration number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source of funding]."
      }
    },
    "total_score": 22,
    "max_score": 25
  },
  "model": "gpt-4o"
}